Byotrol Share Discussion Threads

[football] 15/5/2025 11:20

HTtps://indd.adobe.com/view/f05c264d-3452-47cc-890a-8dfbbe172cccpages 50 - 51

[loafofbread] 07/5/2025 11:45

Not a great day for our Chairman over at his seaweed company.

[football] 02/5/2025 12:52

Like this bit " we will be able to transform the valuation of the Company against its current state and return long-awaited value to stakeholders and shareholders alike"



let's hope it's soonerrather than later

[football] 02/5/2025 12:50

from cliff's link above

Byotrol Limited

("Byotrol" or the "Company")

Trading Update


Byotrol, the specialist infection and prevention control company, is pleased to announce an update on trading.
Results for the year ended 31 March 2025 (FY25), subject to audit, are expected to be reported as follows:
- Total Sales of £4.324m (vs FY24: £3.970m)
- Total Gross Margin: 49.5% (vs FY24: 43.2%, excluding disposal costs of obsolete and discontinued stock)
- Product sales* of £3.869m (vs FY24: £3.902m)
- Product Sales Gross Margin 43.6% (vs FY24: 43.2%, excluding disposal costs of obsolete and discontinued stock)
- Adjusted EBITDA of -£0.100m (vs FY24: -£0.968m)
- Closing cash of £421k (vs FY24: £315k)
In the final quarter of FY25, we concluded the sale of 2 formulations combined with a 5-year licence agreement to our trading partner in Japan for £425k. The sale of these formulations, no longer used by Byotrol in the UK or elsewhere, provides important continuity of supply to our partner given the increased challenge of securing some of the raw materials required here in the UK, whilst also providing Byotrol with an important boost in both cash and profit for the year.
Whilst product sales closed slightly behind FY24, this owed to a difficult Q1 where, as previously mentioned, our sales were suppressed due to significant inventory in the channel following the push in the final quarter of FY24. Q2 to Q4 show year on year growth, giving us a platform from which to progress as we move into the new financial year.
Overall, we remain extremely positive about our position but are well aware that there is much more work to be done. After experiencing an extended period of decline post-Covid, it is clear that the business has finally turned a corner and, since the beginning of Q2 FY25, has started to grow again, marking the end of the first step of our turnaround. The focus now is to accelerate this growth, progress to cash breakeven as quickly as we can, and then onwards to profitability. In doing so, we will be able to transform the valuation of the Company against its current state and return long-awaited value to stakeholders and shareholders alike

[loafofbread] 02/5/2025 09:55

Positive trading update just out. Great effort by the Byotrol team.

[loafofbread] 28/3/2025 16:39

Multiple bidders and back to 0.15 paid.

[football] 28/3/2025 10:06

Seems someone is buying with share price up again and that's 60% of sweet FA it's up in the last 2 days

[football] 25/3/2025 16:22

SP up 10%+ only another 99998566% and we will be all back in profit


hxxps://assetmatch.com/app/OurCompanies/CompanyProfile?companyId=1468

[loafofbread] 01/3/2025 09:40

Hiring a new account manager to join our growing team!

[buywell3] 26/2/2025 04:39

back in 2021






buywell3 - 16 Aug 2021 - 21:50:43 - 8484 of 13007 BYOTROL-CAN DELIVER AMAZING RESULTS - BYOT

Covid-19 is not spread via surfaces --- it is via Aerosols floating around in the air from the infected exhaled breath of some other person or animal in the vicinity

The CDC have said this --- check it out


To date Covid-19 is also not caught from eating food ie by oral intake through you intestinal system

31/1/2021 · According to the CDC, there is no evidence that suggests that COVID-19 can be spread through the handling or consumption of food. Because COVID-19 is an enveloped virus, the virus will die outside of the body, making the transmission of COVID-19 through food highly unlikely.

Which is bloody lucky for all of us when you see the way food gets handled in Supermarkets/shops/cafes/restaurants

The common ground being surface infection --- or in the case of current Covid-19 , the lack of

dyor



























RIP

[football] 07/2/2025 14:30

Byotrol

Our best-practice biosecurity training has made it to the front cover of Vet Nurse Times this month!

[1gw] 22/1/2025 20:38

I think there are some positive signs there - clearly Anigene is doing reasonably well, perhaps byotrol24 isn't dead yet and there's even hope for seaweed - but really it confirms for me that the business was almost killed by a combination of two things.

Firstly the then-board didn't do its job of challenging management effectively when Vivan was selling them his masterplan for rationalising the product set and moving aggressively into Europe. That ate up cash and there's still no sign of a meaningful distributor deal into either Germany or France to replace the UK volume surrendered.

Secondly neither they nor their much bigger IP customers appear to have read the market well. Solvay clearly put resource into and had high hopes for Actizone, Reckitt launched products (outside the US) under a well-known brand and both Ecolab (byotrol24) and SC Johnson (Actizone) got a long way through the US state registration process. But for whatever reason residual disinfection still doesn't seem to be a winner and they've had to give up a lot of the supposedly "guaranteed" IP cashflow, never mind the royalty/commission upside they expected.

They could have done OK I think if one of those hadn't happened i.e. if Vivan's European expansion had worked or if IP receipts had come in anything near what they seem to have been expecting, but the combination of the two hits brought the company to its knees.

They seem to be doing the right thing now, having cut costs and focused on building out Anigene. It's unlikely to be terribly exciting over the next year, but if they can get to positive operating cashflow sometime in FY26 then I think there's still reasonable hope that they can build a decent business.

[loafofbread] 22/1/2025 15:18

Quite a positive read for the first time in years.

Great effort by the Byotrol team.

[football] 22/1/2025 09:54

Byotrol Limited

("Byotrol" or the "Company")

Interim Results and Trading Update


Byotrol Limited, the specialist infection prevention and control company, is pleased to release its unaudited Interim Results for the six months to 30 September 2024 together with a Trading Update for the rest of this current financial year, FY 2025.

Interim Results Highlights:

• Sales of £1,928k (H1 2024: £2,022k)
• Like for like Product Sales, adjusted for discontinuations/exits, £1,892k (H1 2024: £1,827k)
• Product Sales Gross Margin at 43.6% (H1 2024: 42.0% and FY 2024 adjusted: 43.2%)
• EBITDA -£261k (H1 2024: -£448k)
• Closing cash of £409k (H1 2024: £508k)
• Inventories of £263k (H1 2024: £632k)

As communicated in our September update, the first quarter did see a number of challenges within our sales operation, but we are pleased to report a strong recovery in the second quarter that has continued into the third quarter. We are seeing sustained positive trends emerging across the business, including continued growth of the Anigene brand, sales on the Amazon platform exceeding Budget expectations, and our Invirtu formulation growing for the first time since the pandemic.

Trading Update

With the business strengthening in the second quarter, we have completed our Half Year Reforecast and have the following projections for the rest of this financial year, FY 2025:

• Product Sales (exc IP): £4.1m (FY 2024: £4.0m)
• Gross Margin: ~43.8% (FY 2024 adjusted: 43.2%)
• EBITDA: -£0.6m (FY 2024 -£1.0m)

The sales shortfall versus our previously issued projection is due to the impact of the first quarter miss, with second through to fourth quarters recovering and expected to show product sales growth of ~10% versus that same period last year.

IP

As communicated late last year, we have been in negotiation on two of our existing IP agreements. These have now been concluded as below:

a. Rentokil. We have agreed a variation to the existing agreement which has resulted in a final payment of £37.5k being made to Byotrol in exchange for waiving the future payment obligations of Rentokil. The impact of this will result in an exceptional charge of c.£95k in the full year accounts. Rentokil have seen much lower usage than projected of the licenced formulation since entering the agreement in June 2022, prompting the renegotiation which preserves the relationship between us.
b. Integrated Resources International (“IRI”). We learnt in Q3 that the globally recognised hygiene partner who were also involved in the Byotrol24 project in the US alongside IRI were withdrawing from the project. The impact of this is a reduction in the immediate expected volume of orders that IRI will receive once full EPA is granted, now expected later in 2025. In view of this, and to support IRI whilst it builds its customer base for the formal launch of its long-lasting formulation post full EPA approval, we have agreed a final payment of $250k to be made this month, in lieu of the final 2 remaining instalments due of $350k, giving IRI more time and resource to invest in developing their order pipeline. In exchange for this, we have negotiated a higher return on our share of proceeds should IRI sell in the next three years versus the original agreement.

Whilst the above will result in some exceptional charges in the year, they have nevertheless secured cash into the business at an important time to boost liquidity, as well as preserving key commercial relationships that will add value in the future. We will continue to look at select opportunities for IP to generate meaningful cash returns for us, and to support the sustained growth of our product sales operation over the coming months, without unnecessarily compromising long-term asset values.

Board Changes

As part of the restructure in the first quarter, two of our Non-Executive Directors, Trevor Francis and Sean Gogarty, stepped down from their positions. We would like to take this opportunity to formally acknowledge their contributions to Byotrol over several years and wish them well in their future endeavours. Also, and as announced in our September update, David Traynor stepped down from the Board at the end of August and left the business at the end of 2024. David had been with Byotrol since 2013 and has played a key role in transforming the prospects of the business during that period, for which we are thankful. He remains a key shareholder of Byotrol.

Summary

Our objective remains to make the business self-sustainable from product sales alone during FY26, bringing stability whilst also creating the platform for transforming our valuation once we demonstrate a sustainable, profitable business model.

[loafofbread] 09/1/2025 18:23

They have pushed back the auction date for the 4th time? to the 30th January. No doubt to give them more time to finalise their 'positive' negotiations and get the trading update out.

[football] 09/1/2025 13:48

we have a buyer for shares now so is good news coming?

[loafofbread] 08/1/2025 09:43

Looking forward to the 'positive' trading update this week.

[football] 06/1/2025 21:33

need Byotrol to start knocking on Vets and Farmer's doors and show them what our stuff does or take a ad or 2 in trade paper's https://www.telegraph.co.uk/global-health/science-and-disease/us-reports-first-human-h5n1-bird-flu-death/

[mudbath] 23/12/2024 15:24

Happy Christmas indeed; added to that "jam", (alongside a potential further fundraise) sometime in the New Year.

[football] 23/12/2024 10:30

Merry Christmas and a happy New Year

and lets hope for a bettter 2025 to you & Byotrol